Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Krystal Biotech, Inc. (NASDAQ: KRYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Krystal Biotech is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on genetic medicines such as VYJUVEK for dystrophic epidermolysis bullosa and a pipeline of investigational programs in respiratory, ophthalmology, dermatology, oncology, and aesthetics.
Through this page, users can review Form 8‑K current reports in which Krystal Biotech discloses material events. Recent 8‑K filings have covered quarterly financial results, commercial launches of VYJUVEK in new markets such as Japan, regulatory approvals, and key clinical milestones, including updates on trials for KB801 in neurotrophic keratitis and KB304 in aesthetics. These filings often incorporate press releases and slide presentations by reference, providing additional context on the company’s operational and clinical progress.
In addition to 8‑K reports, investors may use this page to navigate to Krystal Biotech’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which contain detailed information on its gene therapy platform, risk factors, financial statements, and segment information related to the development and commercialization of pharmaceutical products. For users interested in governance and compensation matters, proxy statements and related filings can also be accessed.
Stock Titan enhances these documents with AI-powered summaries that explain the key points of lengthy filings, helping readers quickly understand financial results, clinical updates, and regulatory developments without reading every page. Real-time integration with EDGAR ensures that new Krystal Biotech filings, including any future Forms 4 reporting insider transactions, 10‑Q, or 10‑K submissions, appear promptly, while AI-generated highlights point to sections that may be most relevant for KRYS shareholders and analysts.
Krystal Biotech, Inc. reported that President and CEO Krishnan Krish sold 25,000 shares of common stock on March 4, 2026 in multiple open‑market transactions. The weighted average sale prices disclosed in the table range from about $257.31 to $266.56 per share.
The footnotes state these sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to terminate on December 4, 2026 or earlier under its terms. After these sales, Krish directly owned 1,475,253 shares and also had indirect holdings of 90,000 and 50,000 shares through spousal and family trusts.
Krystal Biotech, Inc. Chief Accounting Officer Kathryn Romano reported a mix of stock sales, vesting, and new equity awards. On March 2, 2026, she completed an open-market sale of 750 shares of common stock at $267.60 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 22,366 common shares held directly.
On February 27, 2026, 7,500 performance stock units vested after meeting 2024 performance goals, and 550 restricted stock units vested from a 2025 grant, both converting into common shares. To cover tax withholding on these vestings, 3,262 and 240 common shares, respectively, were surrendered to the company at a reference price of $275.64 per share.
Also on February 27, Romano received new equity incentives: a stock option for 13,575 shares and a new grant of 5,442 restricted stock units, each vesting in four equal annual installments beginning February 27, 2027.
Krystal Biotech President of R&D Suma Krishnan reported multiple equity compensation events and related tax withholdings. On February 27, 2026, 22,500 performance stock units vested after meeting 2024 performance goals, and 4,000 restricted stock units vested from a 2025 grant. Shares were automatically surrendered to the company to cover taxes at a share price of $275.64.
New awards on the same date included 18,100 stock options vesting annually from February 27, 2027, 7,256 time‑based RSUs vesting over four years starting in 2027, and 43,536 performance stock units tied to multi‑year performance criteria through 2029. Additional vested RSUs and PSUs, related tax‑withholding dispositions, and resulting common stock were reported as indirectly owned through the spouse and through family trusts.
Krystal Biotech, Inc.’s President and CEO, Krish S. Krishnan, reported multiple equity compensation events on February 27, 2026. Previously granted restricted stock units and performance stock units vested, converting into shares of common stock for both him and his spouse, Suma M. Krishnan.
Related shares of common stock were surrendered to the company to cover tax withholding obligations at a price of $275.64 per share, classified as tax-withholding dispositions rather than open-market sales. Krishnan also received a new grant of stock options for 45,249 shares and 18,140 restricted stock units, both vesting in equal annual installments beginning on February 27, 2027, subject to continued service.
Additional indirect holdings are reported through Krishnan’s spouse and the Krishnan Family Trust, where he and his spouse share joint voting and investment control.
Krystal Biotech director-linked entity sells shares under trading plan
Alta Bioequities, L.P., an entity associated with Krystal Biotech director Daniel Janney, sold a total of 11,803 shares of the company’s common stock in two open-market transactions on February 27, 2026, at weighted average prices of $275.4487 and $276.1665 per share.
The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on November 25, 2025, which is scheduled to terminate on November 5, 2026, subject to early termination. Alta Bioequities, L.P. continued to hold 73,293 shares after these transactions.
Kathryn Romano reported sales and an intended sale of KRYS common stock. The filing shows 12,500 common shares were sold on 02/09/2026 for $3,401,705.00. It also lists 750 restricted shares tied to vesting as compensation on 02/27/2026.
KRYS reported Form 144 sales by an insider. The filing lists recent sales of Common shares by Daniel S. Janney on 02/24/2026, 02/25/2026, and 02/26/2026, including transactions of 37,895 and 13,825 shares on 02/24/2026. The entries show cash proceeds for each trade in USD.
Krystal Biotech director Daniel Janney reported option exercises and share sales in Krystal Biotech, Inc. common stock. On February 24, 2026, he exercised stock options covering 37,895 shares and received the same number of common shares, then sold those shares in multiple open-market transactions.
On February 24 and 26, 2026, additional open-market sales were reported in accounts indirectly holding shares for Alta Bioequities, L.P., which is managed by an affiliated general partner. The filing notes that Janney’s option exercise and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, 85,096 shares were held indirectly through Alta Bioequities, L.P., while no shares were held directly.